Comparison
17 20 Lyase Deficiency Isolated C3277849 vs 12q14 Microdeletion Syndrome C4305140
Clinical comparison between 17 20 Lyase Deficiency Isolated and 12q14 Microdeletion Syndrome for differential diagnosis and treatment planning.
17 20 Lyase Deficiency Isolated C3277849
A rare enzymatic disorder affecting sex hormone production. Impairs development of sexual characteristics in both males and females. Treatment involves hormone supplementation.
12q14 Microdeletion Syndrome C4305140
A rare genetic deletion involving a segment of chromosome 12. It may lead to developmental delays, learning difficulties, and other health issues. Management is individualized and focuses on supportive therapies.
6 comparison axes
Onset
17 20 Lyase Deficiency Isolated C3277849
0-18
12q14 Microdeletion Syndrome C4305140
0-2
Onset patterns differ
Severity
17 20 Lyase Deficiency Isolated C3277849
severe
12q14 Microdeletion Syndrome C4305140
moderate
Different severity levels
Chronic
17 20 Lyase Deficiency Isolated C3277849
Chronic
12q14 Microdeletion Syndrome C4305140
Chronic
Differing course
Communicable
17 20 Lyase Deficiency Isolated C3277849
No
12q14 Microdeletion Syndrome C4305140
No
Different transmission
Body System
17 20 Lyase Deficiency Isolated C3277849
endocrine
12q14 Microdeletion Syndrome C4305140
congenital
Same/different system
Category
17 20 Lyase Deficiency Isolated C3277849
endocrine
12q14 Microdeletion Syndrome C4305140
genetic
Different category
Bottom line
17-20-lyase-deficiency-isolated-C3277849 and 12q14-microdeletion-syndrome-C4305140 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 17 20 Lyase Deficiency Isolated C3277849 | 12q14 Microdeletion Syndrome C4305140 | Discriminating power |
|---|---|---|---|
| Sexual development | Impaired sex-hormone production may affect puberty or sexual characteristics. | Primary sexual-development disorder is not established from the source description. | High |
| Development and learning | Developmental delay is not a defining feature in the supplied description. | May include developmental delay and learning difficulty. | High |
| Age pattern | Reported onset range is childhood through adolescence, 0–18 years. | Reported onset is early, 0–2 years. | Moderate |
When to favor each condition
Choose 17 20 Lyase Deficiency Isolated C3277849 when
Disordered sexual development
The source centers on impaired sex-hormone production rather than a chromosomal deletion.
High
Endocrine evaluation
Classification is endocrine, with hormone supplementation described as treatment.
Moderate
Later childhood presentation
The supplied onset range extends beyond infancy, unlike the right condition.
Low
Choose 12q14 Microdeletion Syndrome C4305140 when
Early developmental concerns
Source onset is 0–2 years and may include developmental delay.
High
Suspected chromosomal deletion
The condition is described as a rare deletion involving chromosome 12.
High
Need for supportive care
Management is individualized and focuses on supportive therapies.
Moderate
How key tests differ
| Test | 17 20 Lyase Deficiency Isolated C3277849 | 12q14 Microdeletion Syndrome C4305140 | Interpretation |
|---|---|---|---|
| Steroid or sex-hormone assessment | Abnormal hormone pattern may support the enzyme disorder; no cutoff is supplied. | No characteristic hormone result is established here. | An abnormal result is not itself a diagnosis and needs specialist review. |
| Chromosomal microarray | A 12q14 deletion is not expected from the supplied description. | May identify a deletion involving chromosome 12. | Genetic confirmation should be interpreted with clinical findings. |
| Developmental assessment | No specific developmental profile is established. | May document delay or learning difficulty. | Assessment guides support but does not alone confirm either condition. |
Prognosis comparison
17 20 Lyase Deficiency Isolated C3277849
- Outcome
- Chronic and described as severe, but individual outcome is not established.
- Factors
- Hormone effects, timing of recognition, and response to clinician-directed care.
12q14 Microdeletion Syndrome C4305140
- Outcome
- Chronic and described as moderate, with variable developmental and health effects.
- Factors
- Deletion findings, developmental needs, and associated health issues.
Time frame: Long-term; exact course is not established.
Diagnosis confirmation, associated findings, and access to individualized care.
Complications comparison
| Complication | Presentation |
|---|---|
| Pubertal or sexual-development effects | May impair development of sexual characteristics in males and females. Such effects are not established by the source. Severity and exact manifestations vary; clinician assessment is required. |
| Learning and developmental effects | Not described as a core feature. May include developmental delay and learning difficulty. Educational and developmental needs should be assessed individually. |
| Associated health issues | Broader complications and mortality are not established here. Other health issues may occur, but specifics are not supplied. Do not infer unlisted complications from the sparse descriptions. |
Patient education highlights
- HighSpecialist confirmation
Neither label should be assigned from symptoms alone; endocrine or genetics specialists should interpret testing.
- HighDifferent causes
One is an enzyme disorder of sex-hormone production; the other is a chromosomal microdeletion.
- MediumCare planning
Hormone supplementation or supportive therapies may be discussed, but doses and plans must be individualized.